May 10, 2023 / 05:00PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Okay. Welcome to the second day of the BofA Healthcare Conference. My name is Geoff Meacham, and I'm the senior biopharma analyst here at BofA.
We're thrilled today to have Eli Lilly. And speaking on behalf of Lilly is Patrik Jonsson up on stage with me. He's Lilly's EVP and President, Immunology, Lilly USA, Chief Customer Officer, lots of titles.
Patrik Jonsson - Eli Lilly and Company - EVP, Chief Customer Officer, President of Lilly USA & Lilly Immunology
Yes.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystPatrik, give us -- from an I&I perspective, most investors have talked about Mounjaro and Alzheimer's. This is a franchise that has some differentiating assets. It has some -- a great pipeline. So maybe give us a higher level of that franchise and how valuable it is to Lilly today.
Patrik Jonsson - Eli Lilly and